Fentanyl Citrate Inj., USP, CII, 250 mcg/5 mL (50 mcg/mL) (0.05 mg/mL), Rx Only, For IV or IM Use...
FDA Drug Recall #D-1139-2015 — Class III — May 13, 2015
Recall Summary
| Recall Number | D-1139-2015 |
| Classification | Class III — Low risk |
| Date Initiated | May 13, 2015 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | West-Ward Pharmaceutical Corp. |
| Location | Eatontown, NJ |
| Product Type | Drugs |
| Quantity | 14,649 Cartons |
Product Description
Fentanyl Citrate Inj., USP, CII, 250 mcg/5 mL (50 mcg/mL) (0.05 mg/mL), Rx Only, For IV or IM Use Preservative Free, 25 X 5 mL Single Dose Vials per Carton, Manufactured by: West-Ward, Eatontown, NJ 07724 USA, NDC 0641-6028-25.
Reason for Recall
Failed Impurities/Degradation Specifications; 12 month stability testing (Expansion of RES #70548).
Distribution Pattern
Nationwide
Lot / Code Information
Lot #: 043410, Exp 04/2015; 053391, Exp 05/2015; 073340, Exp 07/2015; 083330, 083333, 083335, Exp 08/2015; 093319, 093321, 093323, Exp 09/2015; 103316, 103318, Exp 10/2015
Other Recalls from West-Ward Pharmaceutical Corp.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0172-2015 | Class II | VERSAPHARM INCORPORATED Ethambutol Hydrochlorid... | Oct 2, 2014 |
| D-1414-2014 | Class II | Isoniazid Tablets, USP, 300 mg, Rx only, packag... | May 20, 2014 |
| D-367-2014 | Class II | Carisoprodol Tablets, USP 350 mg, Rx Only, 1000... | Nov 7, 2013 |
| D-66447-002 | Class II | Irinotecan Hydrochloride Injection, 100 mg/5 mL... | Sep 23, 2013 |
| D-66447-001 | Class II | Irinotecan Hydrochloride Injection, 40 mg/2 mL ... | Sep 23, 2013 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.